Tuesday, January 11, 2022
Use of patient-derived stem cells will enable high-throughput drug screening for potential therapeutics.
Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The models development is described in the January issue of the journal Stem Cell Reports. NEI is part of the National Institutes of Health.
This disease-in-a-dish system will help us understand how the absence of pigment in albinism leads to abnormal development of the retina, optic nerve fibers, and other eye structures crucial for central vision, said Aman George, Ph.D., a staff scientist in the NEI Ophthalmic Genetics and Visual Function Branch, and the lead author of the report.
OCA is a set of genetic conditions that affects pigmentation in the eye, skin, and hair due to mutation in the genes crucial to melanin pigment production. In the eye, pigment is present in the retinal pigment epithelium (RPE), and aids vision by preventing the scattering of light. The RPE is located right next to the eyes light-sensing photoreceptors and provides them nourishment and support. People with OCA lack pigmented RPE and have an underdeveloped fovea, an area within the retina that is crucial for central vision. The optic nerve carries visual signals to the brain.
People with OCA have misrouted optic nerve fibers. Scientists think that RPE plays a role in forming these structures and want to understand how lack of pigment affects their development.
Animals used to study albinism are less than ideal because they lack foveae, said Brian P. Brooks, M.D., Ph.D., NEI clinical director and chief of the Ophthalmic Genetics and Visual Function Branch. A human stem cell model that mimics the disease is an important step forward in understanding albinism and testing potential therapies to treat it.
To make the model, researchers reprogrammed skin cells from individuals without OCA and people with the two most common types of OCA (OCA1A and OCA2) into pluripotent stem cells (iPSCs). The iPSCs were then differentiated to RPE cells. The RPE cells from OCA patients were identical to RPE cells from unaffected individuals but displayed significantly reduced pigmentation.
The researchers will use the model to study how lack of pigmentation affects RPE physiology and function. In theory, if fovea development is dependent on RPE pigmentation, and pigmentation can be somehow improved, vision defects associated with abnormal fovea development could be at least partially resolved, according to Brooks.
Treating albinism at a very young age, perhaps even prenatally, when the eyes structures are forming, would have the greatest chance of rescuing vision, said Brooks. In adults, benefits might be limited to improvements in photosensitivity, for example, but children may see more dramatic effects.
The team is now exploring how to use their model for high-throughput screening of potential OCA therapies.
NEI leads the federal governments research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.
About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIHTurning Discovery Into Health
Aman George, Ruchi Sharma, Tyler Pfister, Mones Abu-Asab, Nathan Hotaling, Devika Bose, Charles DeYoung, Justin Chang, David R. Adams, Tiziana Cogliati, Kapil Bharti, Brian P. Brooks. In Vitro Disease Modeling of Oculocutaneous Albinism Type I and II Using Human Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium (2022). doi: 10.1016/j.stemcr.2021.11.01.https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(21)00597-X.
- Benefits of including Giloy to your diet and guide to use it - Newsd.in - January 16th, 2022
- Dr. Khera and Dr. Pearlman discuss innovations in testosterone therapy - Urology Times - January 13th, 2022
- A UVM Researcher Uses Artificial Intelligence and Frog Cells to Create Self-Replicating 'Xenobots' - Seven Days - January 13th, 2022
- Type 1 Diabetes and Sleep: What You Can Do About It - Healthline - January 13th, 2022
- Can You Fight Aging? Scientists Are Testing Drugs to Help - The Wall Street Journal - January 13th, 2022
- What's autophagy? It's the ultimate detox that doesn't yet live up to the hype - The Conversation AU - January 13th, 2022
- CAR-T cell therapy with ASCT brings hope to lymphoma patients - Chinadaily USA - January 11th, 2022
- Umbilical cord blood donations offer hope for those in Japan in need of stem cells - The Japan Times - January 11th, 2022
- Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors... - January 11th, 2022
- Hyperbaric oxygen therapy saved Minnesota man from amputation - The Dickinson Press - January 11th, 2022
- The State of Diabetes Care, 100 Years After the First Insulin Shot - Healthline - January 11th, 2022
- Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR - Business Wire - January 11th, 2022
- Orchard Therapeutics Announces Recent Commercial and Regulatory Progress for Late-stage HSC ... - The Bakersfield Californian - January 11th, 2022
- Cancer Stem Cells Market Overview by Industry Dynamics, Regional Analysis and Forecast 2021 to 2026 Industrial IT - Industrial IT - January 2nd, 2022
- How to reverse your bio age like Tom Brady and Jeff Bezos in 8 weeks - New York Post - January 2nd, 2022
- Pros and Cons of Stem Cell Research Debate: Benefits ... - December 29th, 2021
- Skincare treatments that will dominate 2022 - Times of India - December 29th, 2021
- With soaring demand for meat, it's time to fund animal-free protein research | TheHill - The Hill - December 29th, 2021
- How do some people live past 100 years? Studying rare mutations may crack the scientific mystery - Scroll.in - December 29th, 2021
- The future of Food? From 3D-printed meat-free steaks to edible insect burgers - nation.lk - The Nation Newspaper - December 29th, 2021
- Nonsteroidal Joint Injection Options The Horse - TheHorse.com - December 26th, 2021
- Innovative Methods Legendary Athletes Have Used to Remain the Best - 24/7 Wall St. - December 25th, 2021
- Pork or beef? Stem cells pave the way for lab-grown meat - SYFY WIRE - December 23rd, 2021
- Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options - PRNewswire - December 23rd, 2021
- MESO NUMISMATICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - December 23rd, 2021
- Scientists Used CRISPR Gene Editing to Choose the Sex of Mouse Pups - Singularity Hub - December 23rd, 2021
- What Is Sodium Hyaluronate and How Can It Benefit the Skin? - InStyle - December 23rd, 2021
- Which Tea is the Healthiest? The Benefits of the Most Popular - The Beet - December 19th, 2021
- Viagra associated with reduced risk of Alzheimer's disease - National Institutes of Health - December 19th, 2021
- BMS and Kite Unveil CAR-T Successes in Lymphoma - BioSpace - December 19th, 2021
- Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of... - December 19th, 2021
- 6 Uses and Benefits of CBD On Skin - City Watch - December 19th, 2021
- Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tole - Benzinga - December 12th, 2021
- Politicians Push For Late-Term Abortion Laws to Increase Profits of the Industry's Black Baby Parts Business - BlackNews.com - December 11th, 2021
- Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma ... - The Bakersfield Californian - December 11th, 2021
- Using algae to make cell-based seabass fillets: 'We anticipate that cultured fish can have increased health benefits' - FoodNavigator.com - December 11th, 2021
- Regenerative Medical Center for Stem Cell Treatments MSC+ ... - December 11th, 2021
- Global Stem Cell Partnering Terms and Agreements 2021 Report - Featuring Regenetech, Stempeutics and Arthrex Among Others - ResearchAndMarkets.com -... - December 9th, 2021
- Benefits of Pulsed Laser-based Skin Therapy - Newswise - December 9th, 2021
- What is orthobiologics? - Sanford Health News - December 9th, 2021
- Two year follow up shows delaying umbilical cord clamping saves babies lives - News - The University of Sydney - December 9th, 2021
- PharmaEssentia's BESREMi (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States -... - December 7th, 2021
- Awards and Honors: Winter 2021 | Department of Medicine News | Stanford Medicine - Stanford Medicine - December 7th, 2021
- Here's Why Longeveron Is Surging Today - Motley Fool - December 4th, 2021
- Global Regenerative Medicine Partnering Report/Directory 2021: Terms and Agreements for 1600 Deals 2014-2 - Benzinga - December 4th, 2021
- CAR T-Cell Therapy Market is anticipated to reach US$ 2.8 Bn by 2031 - PRNewswire - December 4th, 2021
- Stem-cell implant prototypes pave the way towards life-long treatment for type 1 diabetes - ZME Science - December 3rd, 2021
- Certain Patients With Heart Failure May Benefit From Stem Cell Therapy - Pharmacy Times - December 3rd, 2021
- Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update - Yahoo Finance - December 3rd, 2021
- Roundtable Discussion: Usmani and Participants Review Using Transplant and Combination Therapy in a Patient With Newly Diagnosed Multiple Myeloma -... - December 3rd, 2021
- Hematopoiesis and innate immunity: an inseparable couple for good and bad times, bound together by an hormetic relationship - DocWire News - December 3rd, 2021
- Reality of universal cancer prevention & cure - BSA bureau - December 3rd, 2021
- World Aids Day Improving the lives of everyone affected by HIV - QMUL - December 3rd, 2021
- Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of... - December 3rd, 2021
- AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and... - November 28th, 2021
- The questions surgical robots still need to answer - Becker's Orthopedic & Spine - November 24th, 2021
- Holiday Gift Guide 2021: The Best Wellness And Self-Care Essentials For Travel - Forbes - November 24th, 2021
- Investigating pathogens and their life cycles, for the benefit of society - MIT News - November 24th, 2021
- Mitigating Toxicities Will Position BCMA for Role in Triple-Class Refractory Multiple Myeloma - OncLive - November 24th, 2021
- Human Primary Cells Market 2021 | Know the Latest COVID19 Impact Analysis and Strategies of Key Players: Lonza, Thermo Fisher Scientific,... - November 21st, 2021
- Researcher Works for Diversity, Inclusion in Sciences, One Journal at a Time - Lab Manager Magazine - November 18th, 2021
- Raw Marijuana Won't Get You Stoned, But It Does Have Some Interesting Benefits - Benzinga - Benzinga - November 16th, 2021
- The 18 Best New November 2021 Skin-Care Launches That Deserve a Spot in Your Routine - Allure - November 16th, 2021
- Singapore Aims To Lead The World In Lab-Grown Meat - Intelligent Living - November 16th, 2021
- Dermarolling Your Scalp Is Proven to Increase Hair Growth and Thickness Here's How to Do It - Yahoo Lifestyle - November 15th, 2021
- Stem Cell Therapy for Heart Failure Reduces CV Events, Death in Select Patientsbut not Hospitalization - AJMC.com Managed Markets Network - November 15th, 2021
- JASPER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - November 15th, 2021
- Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million - Seeking Alpha - November 15th, 2021
- Beam gets green light to begin first clinical test of base editing - BioPharma Dive - November 15th, 2021
- GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition - Galveston County... - November 15th, 2021
- Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference - GlobeNewswire - November 11th, 2021
- Biotech Companies are Expanding the Frontiers of Engineered Cell Therapy - BioSpace - November 11th, 2021
- Fate Therapeutics Announces Abstract Highlighting FT538 and - GlobeNewswire - November 11th, 2021
- Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer... - November 11th, 2021
- Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress - KULR-TV - November 11th, 2021
- Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference - Yahoo Finance - November 9th, 2021
- CELLECTAR BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com - November 9th, 2021
- Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic - PRNewswire - November 9th, 2021
- Technology set to redesign the future of food as agriculture moves towards net zero - ABC News - November 9th, 2021
- MAGENTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - marketscreener.com - November 5th, 2021